1422-肝癌一线靶向药物耐药的表观遗传机制 episode artwork

EPISODE · Aug 12, 2026 · 28 MIN

1422-肝癌一线靶向药物耐药的表观遗传机制

from 聊聊Sci

这篇综述文章详尽阐述了原发性肝癌(HCC)在接受索拉非尼和乐伐替尼等一线靶向药物治疗时产生耐药性的表观遗传机制。作者指出,尽管靶向疗法取得了突破,但多数患者因非编码RNA、DNA/RNA甲基化以及组蛋白修饰的异常调节而出现耐药。这些表观遗传变异通过诱发代谢重编程、逃避程序性细胞死亡、增强肿瘤干细胞特性以及激活替代增殖信号通路等方式,协助癌细胞生存。文章强调,深入理解这些复杂的分子网络对于开发个性化医疗和联合用药方案至关重要。通过靶向特定的表观遗传修饰酶,临床医生有望逆转耐药性并显著提升肝癌患者的长期预后。References:Qi D, Qin Y, Zhu H, et al. Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms[J]. Cell Death & Disease, 2025.前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Aug 12, 2026

Embed this episode

Ready to play

1422-肝癌一线靶向药物耐药的表观遗传机制

0:00 28:27

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 28 minutes long.

When was this 聊聊Sci episode published?

This episode was published on August 12, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!